Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 16

1217P - Profiling of myeloid cells associated with prognosis in nivolumab monotherapy for advanced gastric cancer (WJOG10417GTR study)

Date

10 Sep 2022

Session

Poster session 16

Topics

Tumour Site

Gastric Cancer

Presenters

Hirokazu Shoji

Citation

Annals of Oncology (2022) 33 (suppl_7): S555-S580. 10.1016/annonc/annonc1065

Authors

H. Shoji1, N. Boku1, C. Kudo-Saito2, K. Nagashima3, K. Tsugaru4, N. Takahashi5, T. Kawakami6, Y. Amanuma7, T. Wakatsuki8, N. Okano9, Y. Narita10, Y. Yamamoto11, R. Kizawa12, H. Imazeki1, K. Aoki2, K. Muro10

Author affiliations

  • 1 Department Of Gastrointestinal Medical Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 2 Department Of Immune Medicine, National Cancer Center Research Institute, 104-0045 - Tokyo/JP
  • 3 Biostatistics Unit, Clinical And Translational Research Center, Keio University Hospital, Tokyo/JP
  • 4 Division Of Gastroenterology And Hepatology, Department Of Internal Medicine, Keio University Hospital, Tokyo/JP
  • 5 Department Of Gastroenterology, Saitama Cancer Center, 362-0806 - Saitama/JP
  • 6 Department Of Gastrointestinal Oncology, Shizuoka Cancer Center, 411-8777 - Shizuoka/JP
  • 7 Clinical Trial Promotion Department, Chiba Cancer Center, 260-8717 - Chiba/JP
  • 8 Department Of Gastrointestinal Medical Oncology, The Cancer Institute Hospital of JFCR, 135-8550 - Tokyo/JP
  • 9 Department Of Medical Oncology, Kyorin University of Faculty of Medicine, 181-8611 - Tokyo/JP
  • 10 Department Of Clinical Oncology, Aichi Cancer Center Hospital, 464-8681 - Aichi/JP
  • 11 Department Of Gastroenterology, University of Tsukuba Hospital, 305-8576 - Ibaraki/JP
  • 12 Department Of Medical Oncology, Toranomon Hospital, 105-8470 - Tokyo/JP

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1217P

Background

Because therapeutic efficacy of nivolumab (NIVO) in advanced gastric cancer (AGC) is limited, development of new biomarkers and treatment is necessary. Myeloid cells are the major components in the immune system, and reprogramming abnormal myeloid immunity is likely a promising alternative strategy for improving clinical outcomes. However, it remains unclear which subsets in myeloid cells can be targeted for treating AGC, particularly in combination with immune checkpoint inhibitors.

Methods

In AGC patients receiving NIVO, we conducted flow cytometric analysis of fresh peripheral blood cells (PBCs) before and after NIVO treatment. Overall survival (OS) and progression-free survival (PFS) were compared between the high/low groups divided by the spline-based cutoff value of the proportion of each subset in peripheral blood before treatment. This study was supported by ONO PHARMACEUTICAL CO., LTD. and Bristol Myers Squibb.

Results

Of 100 enrolled patients, 91 were included in the analysis. Four unique subsets in the CD11b+ myeloid cells before NIVO treatment showed significant differences in PFS/OS between high and low groups as shown in the table. Table: 1217P

Subset in myeloid cells group No of patients Median PFS [days] (95%CI) HR (95%CI)P value Median OS [days] (95%CI) HR (95%CI)P value
CD155+ lowhigh 3457 61 (50 - 129)49 (39 - 62) 1.49 (0.96 - 2.32)P = 0.073 248 (160 - NA)167 (115 - 252) 1.69 (1.01 - 2.83)P = 0.044
CD115+ lowhigh 1873 303 (165 - NA)170 (140 - 252) 1.98 (1.16 - 3.37)P = 0.012 99 (57 - 210)49.5 (42 -61) 2.24 (1.15 - 4.37)P = 0.018
B7-H3+ lowhigh 2665 99 (52 - 165)47 (39 - 60) 2.51 (1.50 - 4.18)P < 0.001 393 (153 - NA)167 (140 - 248) 1.84 (1.05 - 3.23)P = 0.032
MARCO+ lowhigh 3358 64 (50 - 146)48 (39 - 61) 1.91 (1.20 - 3.04)P = 0.006 302 (150 - NA)170 (117 - 252) 1.75 (1.04 - 2.94)P = 0.036

Conclusions

Increase of these four myeloid subsets are associated with poor prognosis in NIVO monotherapy for AGC, suggesting that combination therapy targeting B7H3, MARCO, CD115 or CD155 may be candidates for development of new treatment for AGC.

Clinical trial identification

UMIN IDUMIN000032686.

Editorial acknowledgement

Legal entity responsible for the study

Narikazu Boku.

Funding

Ono Pharmaceutical Co.,Ltd. and Bristol-Myers Squibb.

Disclosure

H. Shoji: Financial Interests, Institutional, Research Grant: Takada Pharmaceutical, Ono Pharmaceutical. N. Boku: Financial Interests, Institutional, Research Grant: Takada Pharmaceutical, Ono Pharmaceutical; Financial Interests, Personal, Other, Honorarium: Ono Pharmaceutical, Bristol-Myers Squibb, Taiho Pharmaceutical, Daiichi Sankyo. K. Nagashima: Financial Interests, Personal, Other, Honorarium: Pfizer, Fujimoto Pharmaceutical, SENJU Pharmaceutical, Toray Industries, Inc.. N. Takahashi: Financial Interests, Personal, Other, Honorarium: Ono Pharmaceutical, Bristol-Myers Squibb, Taiho Pharmaceutical. T. Kawakami: Financial Interests, Personal, Other, Honorarium: Ono Pharmaceutical, Bristol-Myers Squibb. N. Okano: Financial Interests, Personal, Other, Honorarium: Taiho Pharmaceutical, Eli Lilly Japan, Eisai, Bayel, Chugai, Ono Pharmaceutical, Takeda, GlaxoSmithKline. Y. Narita: Financial Interests, Personal, Other, Honorarium: Eli Lilly, Daiichi Sankyo, Taiho, Ono Pharmaceutical, Brstol-Myers Squibb. Y. Yamamoto: Financial Interests, Personal, Other, Honorarium: Takeda, Chugai, Taiho, Sanofi, Yakult, Nihon Servier, Lilly, Asahi Kasei Parma, Ono Pharmaceutical. K. Muro: Financial Interests, Personal, Other, Honorarium: Amgen, AstraZeneca, Ono Pharmaceutical, Chugai, Eli Lilly, Daiichi Sankyo, Taiho, Brstol-Myers Squibb. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.

  • Analytics cookies help us improve our website by collecting and reporting information on its usage.

  • We use marketing cookies to build a profile of you as a user through your actions on our site in order to better understand your interests and provide you with pertinent suggestions.